Cargando…

Utility of autoimmune serology testing in the assessment of uncharacterized interstitial lung disease: a large retrospective cohort review

BACKGROUND: Autoimmune serologies are often obtained in the initial evaluation of uncharacterized interstitial lung disease (ILD). Whether this practice is helpful in delineating connective-tissue disease related ILD (CTD-ILD) is not well known. We assessed the frequency of incident CTD-ILD as detec...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsumrain, Mohammad, De Giacomi, Federica, Mirza, Shireen, Moua, Teng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568060/
https://www.ncbi.nlm.nih.gov/pubmed/28830432
http://dx.doi.org/10.1186/s12931-017-0644-4
_version_ 1783258795715067904
author Alsumrain, Mohammad
De Giacomi, Federica
Mirza, Shireen
Moua, Teng
author_facet Alsumrain, Mohammad
De Giacomi, Federica
Mirza, Shireen
Moua, Teng
author_sort Alsumrain, Mohammad
collection PubMed
description BACKGROUND: Autoimmune serologies are often obtained in the initial evaluation of uncharacterized interstitial lung disease (ILD). Whether this practice is helpful in delineating connective-tissue disease related ILD (CTD-ILD) is not well known. We assessed the frequency of incident CTD-ILD as detected by autoimmune serology testing and presenting clinical signs and symptoms. METHODS: Consecutive patients seen at our institution over a four year period with newly diagnosed uncharacterized ILD and autoimmune serologic testing were included. Serologic assessment was performed as a standardized order set of 13 laboratory tests. Presenting demographics and clinical signs or symptoms suggestive of autoimmune disease were correlated with the presence or absence of positive serology studies and final CTD-ILD diagnoses. RESULTS: Overall prevalence of newly diagnosed CTD-ILD was 6.9% (42 of 605). Positive serology was seen in 35.2% (213 of 605) of screened ILD. CTD-ILD was diagnosed in 19.2% of those with positive serology, and 52.8% of those with both positive serology and suggestive clinical signs or symptoms. Only 1.4% of those with positive serology and negative review of systems were diagnosed with CTD-ILD. CTD-ILD diagnoses were made more frequently in younger patients ≤60 years with no diagnoses made after the age of 80 (P = 0.009). Positive serology in non-CTD-ILD cases did not appear to confer any survival advantage. CONCLUSIONS: The yield of autoimmune serology testing in uncharacterized ILD appears greatest in those with suggestive clinical signs or symptoms on presentation for CTD-ILD.
format Online
Article
Text
id pubmed-5568060
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55680602017-08-29 Utility of autoimmune serology testing in the assessment of uncharacterized interstitial lung disease: a large retrospective cohort review Alsumrain, Mohammad De Giacomi, Federica Mirza, Shireen Moua, Teng Respir Res Research BACKGROUND: Autoimmune serologies are often obtained in the initial evaluation of uncharacterized interstitial lung disease (ILD). Whether this practice is helpful in delineating connective-tissue disease related ILD (CTD-ILD) is not well known. We assessed the frequency of incident CTD-ILD as detected by autoimmune serology testing and presenting clinical signs and symptoms. METHODS: Consecutive patients seen at our institution over a four year period with newly diagnosed uncharacterized ILD and autoimmune serologic testing were included. Serologic assessment was performed as a standardized order set of 13 laboratory tests. Presenting demographics and clinical signs or symptoms suggestive of autoimmune disease were correlated with the presence or absence of positive serology studies and final CTD-ILD diagnoses. RESULTS: Overall prevalence of newly diagnosed CTD-ILD was 6.9% (42 of 605). Positive serology was seen in 35.2% (213 of 605) of screened ILD. CTD-ILD was diagnosed in 19.2% of those with positive serology, and 52.8% of those with both positive serology and suggestive clinical signs or symptoms. Only 1.4% of those with positive serology and negative review of systems were diagnosed with CTD-ILD. CTD-ILD diagnoses were made more frequently in younger patients ≤60 years with no diagnoses made after the age of 80 (P = 0.009). Positive serology in non-CTD-ILD cases did not appear to confer any survival advantage. CONCLUSIONS: The yield of autoimmune serology testing in uncharacterized ILD appears greatest in those with suggestive clinical signs or symptoms on presentation for CTD-ILD. BioMed Central 2017-08-23 2017 /pmc/articles/PMC5568060/ /pubmed/28830432 http://dx.doi.org/10.1186/s12931-017-0644-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Alsumrain, Mohammad
De Giacomi, Federica
Mirza, Shireen
Moua, Teng
Utility of autoimmune serology testing in the assessment of uncharacterized interstitial lung disease: a large retrospective cohort review
title Utility of autoimmune serology testing in the assessment of uncharacterized interstitial lung disease: a large retrospective cohort review
title_full Utility of autoimmune serology testing in the assessment of uncharacterized interstitial lung disease: a large retrospective cohort review
title_fullStr Utility of autoimmune serology testing in the assessment of uncharacterized interstitial lung disease: a large retrospective cohort review
title_full_unstemmed Utility of autoimmune serology testing in the assessment of uncharacterized interstitial lung disease: a large retrospective cohort review
title_short Utility of autoimmune serology testing in the assessment of uncharacterized interstitial lung disease: a large retrospective cohort review
title_sort utility of autoimmune serology testing in the assessment of uncharacterized interstitial lung disease: a large retrospective cohort review
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568060/
https://www.ncbi.nlm.nih.gov/pubmed/28830432
http://dx.doi.org/10.1186/s12931-017-0644-4
work_keys_str_mv AT alsumrainmohammad utilityofautoimmuneserologytestingintheassessmentofuncharacterizedinterstitiallungdiseasealargeretrospectivecohortreview
AT degiacomifederica utilityofautoimmuneserologytestingintheassessmentofuncharacterizedinterstitiallungdiseasealargeretrospectivecohortreview
AT mirzashireen utilityofautoimmuneserologytestingintheassessmentofuncharacterizedinterstitiallungdiseasealargeretrospectivecohortreview
AT mouateng utilityofautoimmuneserologytestingintheassessmentofuncharacterizedinterstitiallungdiseasealargeretrospectivecohortreview